Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from efavirenz to Kaletra for cognitive function in virologically suppressed HIV-1 patients
2011-005581-37Phase 4Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lopinavir + ritonavir and efavirenz in human immunodeficiency virus infection (HIV), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Change from baseline in CogState neurocognitive score at 10 weeks after switch from efavirenz to Kaletra. Started Aug 2012; status: completed.
02
Drugs
lopinavir + ritonavirefavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2011-005581-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005581-37.